(SANA) Sana Biotechnology - Overview

Sector: Healthcare | Industry: Biotechnology | Exchange: NASDAQ (USA) | Market Cap: 918m USD | Total Return: 119.6% in 12m

Cell Therapy, Diabetes Treatment, Autoimmune Disease, Cancer Therapy
Total Rating 35
Safety 66
Buy Signal -0.45
Biotechnology
Industry Rotation: +1.7
Market Cap: 918M
Avg Turnover: 8.68M USD
ATR: 8.21%
Peers RS (IBD): 21.3
Risk 5d forecast
Volatility105%
Rel. Tail Risk-16.3%
Reward TTM
Sharpe Ratio1.16
Alpha45.96
Character TTM
Beta1.515
Beta Downside2.284
Drawdowns 3y
Max DD88.11%
CAGR/Max DD-0.14
EPS (Earnings per Share) EPS (Earnings per Share) of SANA over the last years for every Quarter: "2021-03": -0.45, "2021-06": -0.32, "2021-09": -0.46, "2021-12": -0.6, "2022-03": -0.47, "2022-06": -0.39, "2022-09": -0.45, "2022-12": -0.38, "2023-03": -0.43, "2023-06": -0.59, "2023-09": 0.02, "2023-12": -0.41, "2024-03": -0.32, "2024-06": -0.32, "2024-09": -0.25, "2024-12": -0.23, "2025-03": -0.2, "2025-06": -0.39, "2025-09": -0.16, "2025-12": -0.16,
EPS CAGR: 34.04%
EPS Trend: 55.7%
Last SUE: -0.22
Qual. Beats: 0
Revenue Revenue of SANA over the last years for every Quarter: 2021-03: 0, 2021-06: 0, 2021-09: 0, 2021-12: 0, 2022-03: 0, 2022-06: 0, 2022-09: 0, 2022-12: 0, 2023-03: 0, 2023-06: 0, 2023-09: 0, 2023-12: 0, 2024-03: 0, 2024-06: 0, 2024-09: 0, 2024-12: 15.282, 2025-03: 0, 2025-06: 0, 2025-09: 0, 2025-12: 0,
Rev. CAGR: 0.00%
Rev. Trend: 19.6%
Last SUE: 0.00
Qual. Beats: 0

Warnings

Interest Coverage Ratio -4.0 is critical

Altman Z'' -15.00 < 1.0 - financial distress zone

Volatile

Tailwinds

No distinct edge detected

Description: SANA Sana Biotechnology

Sana Biotechnology, Inc. (SANA) is a US-based biotechnology company specializing in engineered cell therapies. The company focuses on both ex vivo (cells engineered outside the body) and in vivo (cells engineered inside the body) platforms, addressing therapeutic areas such as type 1 diabetes, autoimmune diseases, and oncology. The biotechnology sector is characterized by high research and development costs and lengthy product development cycles.

Sanas pipeline includes several cell therapy candidates. UP421, an allogeneic primary islet cell product, is in Phase 1 for type 1 diabetes. SC451, a stem cell-derived pancreatic islet cell therapy, is preclinical for type 1 diabetes. SC291, an allogeneic CAR T cell product, is in Phase 1 for systemic lupus erythematosus and ANCA-associated vasculitis, with preclinical work for other autoimmune indications. SG299, a CD8-targeted fusosome, is in preclinical development for hematologic malignancies and autoimmune diseases. SC262, a hypoimmune-modified CAR T program, is in Phase 1 for non-Hodgkins lymphoma. The business model relies on developing novel cell-based treatments, often involving complex manufacturing processes.

Sana also holds strategic agreements, including an option and license with Beam Therapeutics Inc. for CRISPR Cas12b nuclease editing technology and a license with Harvard College for hypoimmune-modified cell intellectual property. These collaborations are common in the biotechnology industry to leverage specialized technologies and intellectual property. For more detailed financial and pipeline analysis, consider continuing your research on ValueRay.

Headlines to Watch Out For
  • Clinical trial results for lead product candidates impact stock volatility
  • Regulatory approvals for cell therapies drive future revenue
  • Competition in cell therapy market affects market share
  • Research and development expenses impact profitability
  • Strategic partnerships and licensing agreements generate revenue
Piotroski VR‑10 (Strict) 0.5
Net Income: error (cannot be calculated; needs Net Income TTM and Revenue TTM)
FCF/TA: -0.35 > 0.02 and ΔFCF/TA 16.49 > 1.0
NWC/Revenue: error (cannot be calculated; needs Current Assets/Liabilities and Revenue current+prev)
CFO/TA -0.35 > 3% & CFO -143.8m > Net Income -244.2m
Net Debt/EBITDA: error (EBITDA <= 0)
Current Ratio: 1.89 > 1.5 & < 3
Outstanding Shares: last quarter (253.2m) vs 12m ago 7.17% < -2%
Gross Margin: error (current vs previous; cannot be calculated due to missing/invalid data or negative margin)
Asset Turnover: 0.0% > 50% (prev 3.05%; Δ -3.05% > 0%)
Interest Coverage Ratio: -4.04 > 6 (EBITDA TTM -183.0m / Interest Expense TTM 48.4m)
Altman Z'' -15.00
A: 0.17 (Total Current Assets 148.7m - Total Current Liabilities 78.7m) / Total Assets 416.9m
B: -4.44 (Retained Earnings -1.85b / Total Assets 416.9m)
C: -0.43 (EBIT TTM -195.8m / Avg Total Assets 459.0m)
D: -7.22 (Book Value of Equity -1.85b / Total Liabilities 256.0m)
Altman-Z'' Score: -23.81 = D
What is the price of SANA shares? As of April 17, 2026, the stock is trading at USD 3.47 with a total of 2,048,093 shares traded.
Over the past week, the price has changed by +11.22%, over one month by +6.12%, over three months by -24.24% and over the past year by +119.62%.
Is SANA a buy, sell or hold? Sana Biotechnology has received a consensus analysts rating of 4.38. Therefore, it is recommended to buy SANA.
  • StrongBuy: 4
  • Buy: 3
  • Hold: 1
  • Sell: 0
  • StrongSell: 0
What are the forecasts/targets for the SANA price?
Analysts Target Price 8.6 147%
Sana Biotechnology (SANA) - Fundamental Data Overview as of 17 April 2026
P/B = 5.7061
Revenue TTM = 0.0 USD
EBIT TTM = -195.8m USD
EBITDA TTM = -183.0m USD
Long Term Debt = 78.9m USD (from capitalLeaseObligations, last quarter)
Short Term Debt = 14.9m USD (from shortTermDebt, last quarter)
Debt = 78.9m USD (from shortLongTermDebtTotal, last quarter)
Net Debt = -59.5m USD (recalculated: Debt 78.9m - CCE 138.4m)
Enterprise Value = 858.5m USD (918.0m + Debt 78.9m - CCE 138.4m)
Interest Coverage Ratio = -4.04 (Ebit TTM -195.8m / Interest Expense TTM 48.4m)
EV/FCF = -5.93x (Enterprise Value 858.5m / FCF TTM -144.8m)
FCF Yield = -16.86% (FCF TTM -144.8m / Enterprise Value 858.5m)
 FCF Margin = unknown (Revenue TTM is 0 or missing)
 Net Margin = unknown
 Gross Margin = unknown ((Revenue TTM 0.0 - Cost of Revenue TTM 9.56m) / Revenue TTM)
 Tobins Q-Ratio = 2.06 (Enterprise Value 858.5m / Total Assets 416.9m)
 Interest Expense / Debt = 61.37% (Interest Expense 48.4m / Debt 78.9m)
 Taxrate = 21.0% (US default 21%)
NOPAT = -154.7m (EBIT -195.8m * (1 - 21.00%)) [loss with tax shield]
Current Ratio = 1.89 (Total Current Assets 148.7m / Total Current Liabilities 78.7m)
Debt / Equity = 0.49 (Debt 78.9m / totalStockholderEquity, last quarter 160.9m)
 Debt / EBITDA = 0.33 (negative EBITDA) (Net Debt -59.5m / EBITDA -183.0m)
 Debt / FCF = 0.41 (negative FCF - burning cash) (Net Debt -59.5m / FCF TTM -144.8m)
 Total Stockholder Equity = 172.0m (last 4 quarters mean from totalStockholderEquity)
RoA = -53.20% (Net Income -244.2m / Total Assets 416.9m)
RoE = -142.0% (Net Income TTM -244.2m / Total Stockholder Equity 172.0m)
RoCE = -78.05% (EBIT -195.8m / Capital Employed (Equity 172.0m + L.T.Debt 78.9m))
 RoIC = -89.94% (negative operating profit) (NOPAT -154.7m / Invested Capital 172.0m)
 WACC = 10.42% (E(918.0m)/V(996.9m) * Re(11.31%) + (debt cost/tax rate unavailable))
Discount Rate = 11.31% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: 100.0 | Cagr: 13.29%
 [DCF] Fair Price = unknown (Cash Flow -144.8m)
 EPS Correlation: 55.71 | EPS CAGR: 34.04% | SUE: -0.22 | # QB: 0
Revenue Correlation: 19.60 | Revenue CAGR: 0.0% | SUE: 0.0 | # QB: 0
EPS next Quarter (2026-06-30): EPS=-0.15 | Chg7d=+0.010 | Chg30d=+0.010 | Revisions Net=+0 | Analysts=3
EPS current Year (2026-12-31): EPS=-0.58 | Chg7d=+0.010 | Chg30d=+0.010 | Revisions Net=+0 | Growth EPS=+13.4% | Growth Revenue=+0.0%
EPS next Year (2027-12-31): EPS=-0.53 | Chg7d=+0.080 | Chg30d=+0.080 | Revisions Net=+0 | Growth EPS=+8.5% | Growth Revenue=+0.0%
[Analyst] Revisions Ratio: +0.00 (1 Up / 1 Down within 30d for Current Year)
External Resources
Dataroma Stockcircle